Aurobindo gets USFDA nod for Cefdinir capsule

Hyderabad-based bulk drugs major, Aurobindo Pharma, has received an approval from the US Food and Drug Administration (USFDA) to market its 300mg Cefdinir capsules in the US market.

The drug falls under the anti-bacterial segment and is a generic equivalent of the US-based Abbott Laboratories' Omnicef.

Earlier, Aurobindo also received the final approval for 125 mg/5 ml and 250 mg/5 ml oral suspension of this drug from the USFDA.

This is the company's 62nd abbreviated new drug application (ANDA) approval from the USFDA.